Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Treatment dilemma

  • Emma-Jane McDonald
  • Emma-Jane McDonald's Avatar Topic Author
1 month 2 weeks ago - 1 month 2 weeks ago #1944 by Emma-Jane McDonald
Treatment dilemma was created by Emma-Jane McDonald
My patient is 52 with CML and presented in 2010 with a white cell count of 370, Hasford score – intermediate risk, Sokal score 1.12 – intermediate risk.

She was commenced on hydroxyurea and entered into the TIDELL II study.

May 2011 she switched to nilotinib because of residual BCR-ABL positivity of 1.5%

Still not achieved MMR in August 2013, mutation analysis confirmed L445P mutation

MMR achieved November 2013 >3 years post-treatment start date

BCR-ABL ranging between 0.017-0.009 since Feb 2022

Nilotinib dose reduced to 300mg BD in November 2020 because of associated increased cardiovascular risk – she does not have any other risk factors at this stage.

Would you consider her for a trial of stopping treatment at all?

Thank you
Last edit: 1 month 2 weeks ago by arlene.
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
1 month 2 weeks ago #1945 by Tim Hughes
Replied by Tim Hughes on topic Treatment dilemma
It looks like you are finally getting good control of your patient’s disease with nilotinib after 12 years but her BCR::ABL1 values are still not in the MR4.5 range. While a TFR attempt would be tempting I don’t think she would have a great chance of success at this stage given her imatinib treatment failure, a KD mutation and lack of prolonged MR4. On the other hand continuing her nilotinib therapy – even at the lower dose is starting to get quite risky from a cardiovascular perspective. Exposure of more than 5 years of nilotinib is associated with high rates of arterial occlusive events, even for patients who were low risk for CVS disease initially.

The options here would be to lower her nilotinib dose further to 300 mg daily, switch to low dose dasatinib (50 mg/day) or switch to asciminib 80 mg daily. You could argue that it would be better to wait until she is in the MR4.5 range before making any change but I am more concerned about vascular events after such a long exposure to full dose nilotinib, so I would probably make a change now. Personally, I would switch her to asciminib but I am not sure if that is possible in NZ in this setting. If not I would probably switch to low dose dasatinib. If the preference of the patient is to remain on nilotinib then I would go for a lower dose.
Moderators: Nicolaarlene